Combo Product Start-Ups Should Start Small, Commercialize Early – Ekos CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Device start-ups developing combo products should steer clear of “Big Pharma,” launch relatively simple 510(k) devices to generate immediate revenue, panelists advise at recent Wilson Sonsini Goodrich & Rosati Medical Device Conference in San Jose.
You may also be interested in...
Angiotech Pharma Looks To Become Less Reliant On Device Partners
Dependence on Boston Scientific's Taxus royaltieis will fall significantly once Angiotech offers AMI's oncology, aesthetic, wound closure and ophthalmology devices.
Inamed’s Board Embraces Allergan’s Offer After Dissolving Deal With Medicis
Allergan may be forced to divest more than Inamed's development-stage botulinum toxin type A product, Reloxin.
Off-Label Promotion Not Enough For Fed Intervention – Patton Boggs Lawyer
Justice Department is unlikely to investigate off-label drug claims unless a firm is also offering kickbacks or bilking Medicare or Medicaid, Laura Laemmle asserts, discussing recent case against drug firm Serono.